Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
about
Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
P2860
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@ast
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@en
type
label
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@ast
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@en
prefLabel
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@ast
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@en
P2093
P2860
P1433
P1476
Molecular mechanism of PD-1/PD ...... s atezolizumab and durvalumab.
@en
P2093
Heejin Lim
Hyo Jeong Pyo
Hyun Tae Lee
Ju Yeon Lee
Sang Hyung Lee
Seong Eon Ryu
Woori Shin
Yong-Seok Heo
Yu Jeong Moon
P2860
P2888
P356
10.1038/S41598-017-06002-8
P407
P577
2017-07-17T00:00:00Z
P6179
1090637439